Literature DB >> 27248627

CDX2 as a Prognostic Biomarker in Colon Cancer.

Piero Dalerba, Debashis Sahoo, Michael F Clarke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27248627      PMCID： PMC4955394          DOI： 10.1056/NEJMc1602584

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.

Authors:  Jung Ho Kim; Ye-Young Rhee; Jeong Mo Bae; Nam-Yun Cho; Gyeong Hoon Kang
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

2.  Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.

Authors:  Jeong Mo Bae; Tae Hun Lee; Nam-Yun Cho; Tae-You Kim; Gyeong Hoon Kang
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

3.  Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions.

Authors:  Felipe De Sousa E Melo; Xin Wang; Marnix Jansen; Evelyn Fessler; Anne Trinh; Laura P M H de Rooij; Joan H de Jong; Onno J de Boer; Ronald van Leersum; Maarten F Bijlsma; Hans Rodermond; Maartje van der Heijden; Carel J M van Noesel; Jurriaan B Tuynman; Evelien Dekker; Florian Markowetz; Jan Paul Medema; Louis Vermeulen
Journal:  Nat Med       Date:  2013-04-14       Impact factor: 53.440
  3 in total
  8 in total

1.  Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.

Authors:  Irit Ben-Aharon; Tal Goshen-Lago; Michal Sternschuss; Sara Morgenstern; Ravit Geva; Alexander Beny; Ygael Dror; Mariana Steiner; Ayala Hubert; Efraim Idelevich; Katerina Shulman; Moshe Mishaeli; Sophia Man; Nicky Liebermann; Lior Soussan-Gutman; Baruch Brenner
Journal:  Oncologist       Date:  2019-02-12

Review 2.  Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions.

Authors:  U Bender; Y S Rho; I Barrera; S Aghajanyan; J Acoba; P Kavan
Journal:  Curr Oncol       Date:  2019-11-01       Impact factor: 3.677

3.  Homeobox protein CDX2 as a prognostic biomarker in solid malignancies: a meta-analysis.

Authors:  Jingsheng Yuan; Zhijie Yin; Kaixiong Tao; Guobing Wang; Jinbo Gao
Journal:  Oncotarget       Date:  2017-09-11

4.  Transcriptional profiling of lung macrophages identifies a predictive signature for inflammatory lung disease in preterm infants.

Authors:  Debashis Sahoo; Livia S Zaramela; Gilberto E Hernandez; Uyen Mai; Sahar Taheri; Dharanidhar Dang; Ashley N Stouch; Rachel M Medal; Alyssa M McCoy; Judy L Aschner; Timothy S Blackwell; Karsten Zengler; Lawrence S Prince
Journal:  Commun Biol       Date:  2020-05-22

5.  PITX2 enhances progression of lung adenocarcinoma by transcriptionally regulating WNT3A and activating Wnt/β-catenin signaling pathway.

Authors:  Jing Luo; Yu Yao; Saiguang Ji; Qi Sun; Yang Xu; Kaichao Liu; Qiang Diao; Yong Qiang; Yi Shen
Journal:  Cancer Cell Int       Date:  2019-04-11       Impact factor: 5.722

6.  Boolean implication analysis unveils candidate universal relationships in microbiome data.

Authors:  Daniella Vo; Shayal Charisma Singh; Sara Safa; Debashis Sahoo
Journal:  BMC Bioinformatics       Date:  2021-02-05       Impact factor: 3.169

7.  Prognostic Impact of An Integrative Landscape of Clinical, Immune, and Molecular Features in Non-Metastatic Rectal Cancer.

Authors:  Soledad Iseas; Juan M Sendoya; Juan Robbio; Mariana Coraglio; Mirta Kujaruk; Vanesa Mikolaitis; Mariana Rizzolo; Ana Cabanne; Gonzalo Ruiz; Rubén Salanova; Ubaldo Gualdrini; Guillermo Méndez; Marina Antelo; Marcela Carballido; Cecilia Rotondaro; Julieta Viglino; Martín Eleta; Alejandro Di Sibio; Osvaldo L Podhajcer; Enrique Roca; Andrea S Llera; Mariano Golubicki; Martín Carlos Abba
Journal:  Front Oncol       Date:  2022-01-07       Impact factor: 6.244

8.  LIN28B induces a differentiation program through CDX2 in colon cancer.

Authors:  Kensuke Suzuki; Yasunori Masuike; Rei Mizuno; Uma M Sachdeva; Priya Chatterji; Sarah F Andres; Wenping Sun; Andres J Klein-Szanto; Sepideh Besharati; Helen E Remotti; Michael P Verzi; Anil K Rustgi
Journal:  JCI Insight       Date:  2021-05-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.